Pioglitazone therapy in progressive differentiated thyroid carcinoma;Pioglitazon-Therapie des fortgeschrittenen differenzierten Schilddrüsenkarzinoms

NuklearMedizin

Volumn 51, Issue 4, 2012, Pages 111-115

  Rosenbaum Krumme, S J ^a   Bockisch, A ^a   Nagarajah, J ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

124I NA; 18F FDG; PET CT; Pioglitazone; Re differentiation; Thyroid cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 124; PIOGLITAZONE; SODIUM IODIDE; SODIUM IODIDE I 124; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIFFERENTIATED THYROID CANCER; DOSIMETRY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; METABOLIC DISORDER; TREATMENT DURATION; TUMOR DIFFERENTIATION; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; THIAZOLIDINEDIONES; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84866448663     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/Nukmed-0474-12-01     Document Type: Article

References (18)

1. Antonelli A, Ferrari SM, Fallahi P et al. Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells. Clin Endocrinol 2009; 70: 946-953.
2. Freudlsperger C, Moll I, Schumacher U et al. Antiproliferative effect of peroxisome proliferator-activated receptor gamma agonists on human malignant melanoma cells in vitro. Anticancer Drugs 2006; 17: 325-332.
3. Fröhlich E, Machicao F, Wahl R. Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture. Endocr Relat Cancer 2005; 12: 291-303.
4. Görges R. Schilddrüsenkarzinome mit Follikelzellursprung. In: Schott M (ed). Moderne Labordiagnostik von Schilddrüsenerkrankungen. Bremen: UniScienceMed, SD-Labordiagnostik, 2011.
5. Jentzen W, Freudenberg L, Eising EG et al. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J Nucl Med 2008; 49: 1017-1023.
6. Jentzen W, Freudenberg L, Eising EG et al. Segmentation of PET volumes by iterative image thresholding. J Nucl Med 2007; 48: 1008-1014.
7. Kebebew E, Lindsay S, Clark OH et al. Results of rosiglitazone therapy in patients with thyroglobulinpositive and radioiodine-negative advanced differentiated thyroid cancer. Thyroid 2009; 19: 953-956.
8. Kebebew E, Peng M, Reiff E et al. A phase II trial of rosiglitazone in patients with thyroglobulin positive and radioiodine-negative differentiated thyroid cancer. Surgery 2006; 140: 960-966.
9. Koeffler HP. Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res 2003; 9: 1-9.
10. Klopper JP, Hays WR, Sharma V et al. Retinoid X receptor- and peroxisome proliferator-activated receptor-y expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. Molecular Cancer Therapeutics 2004; 3: 1011-1020.
11. Padhani AR, Ollivier L. The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists. Br J Radiol 2001; 74: 983-986.
12. Park JW, Zarnegar R, Kanauchi H et al. Troglitazone, the peroxisome proliferator- activated receptor- agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid 2005; 15: 222-231.
13. Philips JC, Petite C, Willi JP et al. Effect of peroxisome proliferator-activated receptor y-agonist, rosiglitazone, on dedifferentiated thyroid cancers. Nucl Med Commun 2004; 25: 1183-1186.
14. Rosenbaum-Krumme SJ, Freudenberg LS, Jentzen W et al. Effects of rosiglitazone on radioiodine negative and progressive differentiated thyroid carcinoma as assessed by 124I-PET/CT imaging. Clin Nucl Med 2012; 37: e47-e52.
15. Tepmongkol S, Keelawat S, Honsawek S et al. Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: A correlation with the expression of peroxisome proliferator-activated receptor-gamma. Thyroid 2008; 18: 697-704.
16. Therasse P, Eisenhauer EA, Buyse M. Update in methodology and conduct of cancer clinical trials. Eur J Cancer 2006; 42: 1322-1330.
17. Young H, Baum R, Cremerius U et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 1999; 35: 1773-1782.
18. Young P, Buckle D, Cantello B et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferatoractivated receptor gamma. J Pharmacol Exp Ther 1998; 284: 751-759.